CR10456A - ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5B1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA - Google Patents

ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5B1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA

Info

Publication number
CR10456A
CR10456A CR10456A CR10456A CR10456A CR 10456 A CR10456 A CR 10456A CR 10456 A CR10456 A CR 10456A CR 10456 A CR10456 A CR 10456A CR 10456 A CR10456 A CR 10456A
Authority
CR
Costa Rica
Prior art keywords
humanized
function
integrin
humans
reduced immunogenicity
Prior art date
Application number
CR10456A
Other languages
English (en)
Inventor
Menrad Andreas
Willuda Jorg
Bosslet Klaus
Zopf Dieter
Petrul Heike
Steidl Stefan
Prassler Josef
Petit-Frere Corinne
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10456A publication Critical patent/CR10456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Polipeptidos recombinantes humanos o humanizados que se unen a la integrina a5B1 con gran afinidad y bloquean su funcion. Ademas, se describen aplicaciones de diagnostico y farmaceutico de los polipeptidos.
CR10456A 2006-05-24 2008-11-24 ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5B1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA CR10456A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
CR10456A true CR10456A (es) 2009-02-26

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10456A CR10456A (es) 2006-05-24 2008-11-24 ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5B1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA

Country Status (23)

Country Link
US (1) US20090081207A1 (es)
EP (1) EP2032605A2 (es)
JP (1) JP2009537158A (es)
KR (1) KR20090027218A (es)
CN (1) CN101495515A (es)
AR (1) AR061107A1 (es)
AU (1) AU2007253586A1 (es)
BR (1) BRPI0711796A2 (es)
CA (1) CA2652886A1 (es)
CL (1) CL2007001488A1 (es)
CR (1) CR10456A (es)
DO (2) DOP20070101A (es)
EA (1) EA200802348A1 (es)
EC (1) ECSP088909A (es)
MA (1) MA30425B1 (es)
MX (1) MX2008014910A (es)
NO (1) NO20085362L (es)
PE (1) PE20080100A1 (es)
TN (1) TNSN08469A1 (es)
TW (1) TW200817433A (es)
UY (1) UY30362A1 (es)
WO (1) WO2007134876A2 (es)
ZA (1) ZA200810850B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
AR060040A1 (es) 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1
TWI547503B (zh) 2007-09-26 2016-09-01 建南德克公司 抗α5β1抗體、編碼其之核酸、包含其之組合物及其製造及使用方法
RU2528736C2 (ru) * 2008-02-05 2014-09-20 Бристоль-Мейерз Сквибб Компани Антитела против альфа5-бета 1 и их применение
ES2663536T3 (es) * 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
CA2742861A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
AU2010229479B2 (en) * 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
WO2012004384A2 (en) * 2010-07-09 2012-01-12 Affibody Ab Polypeptides
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
SI2834244T1 (sl) 2012-03-13 2016-12-30 Respivert Limited Inhibitorji kristalinične PI3 kinaze
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP6502856B2 (ja) * 2012-12-26 2019-04-17 オンコシナジー インコーポレイテッド 抗インテグリンβ１抗体組成物及びその使用方法
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2017001990A1 (en) * 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
EP3916014A4 (en) * 2019-07-24 2022-10-26 Korea Basic Science Institute SINGLE DOMAIN ANTIBODIES TARGETED AGAINST AVSS3 INTEGRIN
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
AU2003298783B2 (en) * 2002-11-26 2010-11-04 Abbvie Biotherapeutics Inc. Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
DK1755659T3 (da) * 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
AR060040A1 (es) * 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1

Also Published As

Publication number Publication date
MA30425B1 (fr) 2009-05-04
TNSN08469A1 (en) 2010-04-14
KR20090027218A (ko) 2009-03-16
MX2008014910A (es) 2009-01-23
AU2007253586A1 (en) 2007-11-29
AR061107A1 (es) 2008-08-06
BRPI0711796A2 (pt) 2011-12-06
TW200817433A (en) 2008-04-16
NO20085362L (no) 2009-02-23
CA2652886A1 (en) 2007-11-29
US20090081207A1 (en) 2009-03-26
UY30362A1 (es) 2008-01-02
JP2009537158A (ja) 2009-10-29
ECSP088909A (es) 2008-12-30
DOP2007000101A (es) 2007-12-31
CN101495515A (zh) 2009-07-29
DOP20070101A (es) 2007-12-30
EA200802348A1 (ru) 2009-08-28
PE20080100A1 (es) 2008-04-18
WO2007134876A3 (en) 2008-03-27
CL2007001488A1 (es) 2008-01-04
WO2007134876A2 (en) 2007-11-29
WO2007134876A8 (en) 2009-07-02
EP2032605A2 (en) 2009-03-11
ZA200810850B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
CR10456A (es) ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5B1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
EP2195017A4 (en) MESOTHELIN BINDING HUMAN ANTIBODY AND ITS USE
EP4271413A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
CR20120105A (es) Proteínas terapéuticas de unión a dll4
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
HUE044756T2 (hu) HER-3 elleni antitestek és alkalmazásuk
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
MX2018012418A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EP4215547A4 (en) SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, ITS FUSION PROTEIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CR9798A (es) Uso de peptidos que se unen al receptor de trombopoyetina
EP4380631A4 (en) Cd3 targeting antibodies and uses thereof
EP4200324A4 (en) MULTIPARATOPIC ANTI-PD-1 ANTIBODIES AND THEIR USES
EP4301784A4 (en) Antibodies against claudin-6 and uses thereof
IL306074A (en) UPAR antibodies and fusion proteins with them
EP4261225A4 (en) ANTI-PD-1 ANTIBODY AND ITS USES
BR0207616B1 (pt) material composto de policarbonato em camadas e seu uso.
EP4389771A4 (en) Fusion protein containing an anti-Tigit antibody and a TGF-beta receptor, and pharmaceutical composition and associated use
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
EP3833690C0 (en) RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2
BRPI0810664A2 (pt) epítopo funcional de osteopontina, o anticorpo monoclonal anti-osteopontina e seu uso.
EP4323412A4 (en) Fusion proteins and uses thereof
EP4319816A4 (en) Anti-venom antibodies and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)